<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01352767</url>
  </required_header>
  <id_info>
    <org_study_id>CP-PP-002</org_study_id>
    <nct_id>NCT01352767</nct_id>
  </id_info>
  <brief_title>The InsuPad in Daily Life Study - Effect of Local Heating on Postprandial Glucose Excursions Using the InsuPad Device</brief_title>
  <official_title>A Randomised, Controlled, Cross-over Study With Inpatient and Outpatient Phases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Insuline Medical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forschungsinstitut der Diabetes Akademie Mergentheim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Insuline Medical Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised, controlled, cross-over study with inpatient and outpatient phases. The&#xD;
      inpatient phase length will be two days, which include a &quot;Control&quot; day without activating the&#xD;
      InSuPad and a &quot;Test&quot; day where the InsuPad is activated. The outpatient phase length is 8&#xD;
      weeks: 4 weeks without the device-&quot;Control&quot;, and 4 weeks with the device-&quot;Test&quot;.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomised, controlled, cross-over study with inpatient and outpatient phases. The&#xD;
      inpatient phase length will be two days, which include a &quot;Control&quot; day without activating the&#xD;
      InSuPad and a &quot;Test&quot; day where the InsuPad is activated. The outpatient phase length is 8&#xD;
      weeks: 4 weeks without the device-&quot;Control&quot;, and 4 weeks with the device-&quot;Test&quot;. Each subject&#xD;
      will be randomly selected into one of two groups, group &quot;A&quot; and group &quot;B&quot;. Forty (40) type I&#xD;
      subjects who are meeting the inclusion/exclusion criteria as outlined below and who provide&#xD;
      written Informed Consent will be enrolled in the study.&#xD;
&#xD;
      During the inpatient phase subjects will have standardized breakfast and dinner and venous&#xD;
      blood samples will be taken for insulin and blood glucose measurements. Comparison of the two&#xD;
      days (&quot;control&quot; and &quot;test&quot;) will enable us to evaluate the effect of the device on post&#xD;
      prandial glucose levels and insulin levels.&#xD;
&#xD;
      During the outpatient (daily life) phase subjects will be required to perform at least 5 self&#xD;
      blood glucose measurements (SMBG), three before each meal and two at 90 minutes post&#xD;
      breakfast and dinner. Comparing the SMBG measurement from the two periods will enable us to&#xD;
      evaluate the effect of the device on post prandial glucose levels. The subjects will be&#xD;
      contacted over the phone by the study staff to verify compliance with the protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy</measure>
    <time_frame>2 hours</time_frame>
    <description>AUC120 BG (area under the curve of postprandial glucose change 2 hours after meal) after breakfast and dinner under standardized conditions during the inpatient phase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>8 weeks</time_frame>
    <description>Mean change in post prandial glucose level at 90 minutes during the outpatient phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>8 weeks</time_frame>
    <description>AUC60 Ins (area under the curve of insulin concentration change 1 hour after meal) after breakfast and dinner under standardized conditions during the inpatient phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>14 weeks</time_frame>
    <description>• Number and severity of hypoglycaemias and hyperglycaemias and assessment of relationship to the use of the InsuPad device during the whole study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction</measure>
    <time_frame>14 weeks</time_frame>
    <description>• Patient satisfaction (subjective clinical performance) at the end of the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Type 1 Diabetes Mellitus With Diabetic Neuralgia</condition>
  <arm_group>
    <arm_group_label>InsuPad Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of the InsuPad which heats the injection site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>InsuPad</intervention_name>
    <description>Heating pad</description>
    <arm_group_label>InsuPad Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients aged 18 to 70 years (values included)&#xD;
&#xD;
          -  Type 1 diabetes mellitus or insulin treated type 2 diabetes with daily insulin demand&#xD;
             ≥ 0.7 units per kg bodyweight.&#xD;
&#xD;
          -  6% ≤ HbA1c ≤ 9.5%&#xD;
&#xD;
          -  Use of short-acting prandial insulin analogues with injections&#xD;
&#xD;
          -  Study subject is willing to perform at least 5 blood glucose measurements per day for&#xD;
             at least 56 days, willing to comply with study procedures and to keep a detailed&#xD;
             patient log book.&#xD;
&#xD;
          -  Willing to sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Excessive fibrosis, lipo-hypertrophy or eczema at injection sites.&#xD;
&#xD;
          -  Known gastro- or enteroparesis.&#xD;
&#xD;
          -  Unstable chronic disease other than type 1 diabetes (e.g. Unstable angina factoris, ,&#xD;
             renal disease) for the last six months before study start.&#xD;
&#xD;
          -  Severe hypoglycemic events requiring glucagon injection or glucose infusion within the&#xD;
             last four weeks prior to study start.&#xD;
&#xD;
          -  Hypoglycaemia unawareness (Score &gt; 4 in the Hypoglycaemia Awareness Questionnaire, see&#xD;
             appendix)&#xD;
&#xD;
          -  Diabetic ketoacidosis (severe, with hospitalization) within the last six months prior&#xD;
             to study start&#xD;
&#xD;
          -  Any known life-threatening disease&#xD;
&#xD;
          -  Pregnant women, lactating women or women who intend to become pregnant during the&#xD;
             observation period&#xD;
&#xD;
          -  Any other condition or compliance issues that might interfere with study participation&#xD;
             or results&#xD;
&#xD;
          -  Subjects with heat sensitivity&#xD;
&#xD;
          -  Subjects involved in or planed to participate in other studies&#xD;
&#xD;
          -  Subjects who are incapable of contracting or under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bad Mergentheim</name>
      <address>
        <city>Bad Mergentheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.insuline-medical.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>May 11, 2011</study_first_submitted>
  <study_first_submitted_qc>May 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2011</study_first_posted>
  <last_update_submitted>September 4, 2014</last_update_submitted>
  <last_update_submitted_qc>September 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>insulin injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

